Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses ongoing research regarding neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian cancer.
Mitchel Hoffman, MD
Advertisement
Articles by Mitchel Hoffman, MD
Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses eligibility criteria for primary debulking surgery versus neoadjuvant chemotherapy in advanced ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Hoffman on Primary Debulking Versus Neoadjuvant Chemotherapy in Ovarian CancerPublished: February 20th 2020 | Updated:
Dr. Hoffman on Research Regarding Neoadjuvant Chemo and Primary Debulking in Ovarian CancerPublished: February 26th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5